Book Description

Now in its second edition, this comprehensive handbook provides a state-of-the-art overview of recent advances in drug and non-drug therapies for obesity and diabetes. It also addresses major comorbidities, covering topics such as, cardiovascular diseases, renal and neuropsychiatric disorders, appetite control and micro RNAs. Special attention is also devoted to pediatric care, including the latest recommendations for therapy and prevention. Obesity and type 2 diabetes are among the top global health-care budget concerns worldwide and impact professional practice at all levels: in hospitals, clinics and physicians’ offices alike. They prominently feature in headlines, and virtually no family, community or country is exempt from their protean, deleterious consequences. Furthermore, given the multiple intersections in their pathways, they often go hand in hand. The good news is that scientific advances in all fields, including genomics, metabolomics, lipidomics and microbiomics, are increasing our understanding of these two disease areas. At the same time, artificial intelligence, machine learning, mobile health and advanced implantable and external devices are rendering prevention and management more available, safe and cost-effective. In addition, bariatric and metabolic surgery has evolved from a niche specialty to an officially endorsed option for several modalities of obesity and diabetes. This book presents the latest lifestyle, pharmacological, surgical and non-surgical treatment options, including endoscopic intervention and cell therapy. Objectively reviewing natural and artificial sweeteners and critically examining issues such as public health initiatives, government mandated taxes for unhealthy foods and environmental planning, no stone is left unturned in gathering the latest practical information. As such, the book will appeal to seasoned specialists, as well as students and healthcare professionals in training.